Plamotamab

- 仁域生物 - 2024年 CD20 肿瘤免疫疗法的最新进展 -从开创性的单克隆抗体到嵌合抗原受体修饰的T细胞- mAbs BsAbs CAR-T 导读 CD20在B细胞的发育、分化和激活中起关键作用，是治疗B细胞恶性肿瘤的重要靶点。抗CD20免疫疗法可特异性靶向B细胞，对其他类型的细胞影响小，停止治疗后B细胞可恢复，且不影响患者的体液免疫。 图1 B 细胞分化和成熟的图表 （通过红色渐变表示的 CD20 表达水平的显著增加） 在当前形势下，抗CD20的免疫疗法快速发展。除了传统的单克隆抗体（mAbs）之外，还有抗体-药物偶联物（ADC）、双特异性抗体（BsAbs）和嵌合抗原受体修饰的T细胞（CAR-T）等。 图2 CD20 免疫疗法的临床批准和最新突破的时间顺序 尽管取得了重大进展，但与这些疗法相关的不良事件和耐药性的发展仍然是关键问题。了解和缓解这些挑战对于抗CD20免疫疗法的持续成功至关重要。 CD20抗原概述 1. CD20的结构：CD20是一种在B细胞上表达的跨膜蛋白，属于MS4A家族。其结构包括四个跨膜螺旋和两个细胞外环，是抗CD20-mAbs的主要识别表位。 图3 CD20 的结构 2. CD20的功能：CD20在B细胞膜上与其他蛋白质相互作用形成纳米簇，维持B细胞静息状态。 图4 CD20的表达调控机制 3. CD20的表达调控：CD20的表达受基因、转录因子、表观遗传水平等多重调控。 抗CD20单克隆抗体及免疫偶联物 01 mAbs的发展 抗CD20-mAbs的发展趋势是提高兼容性和降低免疫原性。第一代药物利妥昔单抗是嵌合鼠-人结构，后续的奥滨尤妥珠单抗为糖工程化人源化抗体，奥法木单抗是全人源抗体。新一代抗体免疫原性降低，与免疫效应细胞和FcRn受体的相互作用增强，半衰期延长。 02 作用机制 抗CD20-mAbs通过至少四种机制发挥细胞毒性作用，包括激活补体介导的细胞毒性（CDC）、介导抗体依赖性细胞毒性（ADCC）和吞噬作用（ADCP）以及直接诱导细胞死亡。 图5 抗 CD20 单克隆抗体的已知作用机制 以及影响恶性 B 细胞对抗 CD20 治疗耐药性的潜在因素 根据其对CD20的作用方式，可分为两类：I型mAbs（如利妥昔单抗、奥法木单抗和ublituximab）能使CD20聚集成膜脂筏，强力诱导CDC，但内化率较高；II型mAbs（如奥滨尤妥珠单抗）不诱导CD20在脂筏中聚集，CDC作用较弱，但能直接诱导细胞死亡。 03   临床应用与疗效 1 利妥昔单抗是首个用于癌症治疗的mAb，对多种B细胞恶性肿瘤有效，但其存在Trogocytosis、补体耗尽、CD20内化等耐药机制。目前与来那度胺、mTOR抑制剂等多种联合用药策略来提高其疗效。 2 奥法木单抗虽在临床前研究中CDC诱导能力更强，但临床证据有限，在某些治疗中未显示出优于其他抗CD20药物的效果。 3 Ublituximab虽未获批但在临床试验中展现出了明显疗效且探索了联合治疗，严重并发症少见。 4 奥滨尤妥珠单抗在CLL和FL的一线治疗中表现出较好疗效，其通过糖工程化修饰提高了与FcγRIII的结合能力，具有更强的ADCC活性，且不易被内化。 表1 不同抗CD20单克隆抗体作用机制 04 免疫偶联物 CD20-mAbs也可作为免疫偶联物使用，包括与药物（ADCs）、毒素（免疫毒素或工程毒素体-ETBs）或放射性同位素（放射免疫偶联物）连接。但因多种因素（如增加继发性恶性肿瘤和骨髓毒性风险、经济和物流问题等）未广泛应用。 表2 临床批准和测试的抗 CD20 mAb 和放射免疫偶联物 CD20双特异性抗体 概述：CD20-BsAbs可同时靶向两种抗原或同一抗原的两个表位，能桥接免疫细胞与肿瘤细胞，增强细胞毒性。有多种分子格式，包括IgG样和非IgG样平台，IgG型BsAbs具有Fc区，可介导ADCC和CDC，非IgG型BsAbs主要通过直接抗原结合发挥作用。 表3 临床批准和测试的 CD20xCD3 BsAbs 1 Epcoritamab是全长IgG1的CD20xCD3-BsAb。2023年获FDA和EMA批准用于r/r-DLBCL治疗。 2 Odronextamab是铰链稳定的全人IgG4的CD20xCD3-BsAb。2023年获FDA和EMA批准用于r/r-FL治疗。 3 Mosunetuzumab是全长人源化IgG1的CD20xCD3 BsAb。2022年获EMA有条件批准，2023年获FDA批准用于成人r/rFL治疗。 4 Glofitamab是异二聚体人IgG1的CD20xCD3-BsAb。2023年获FDA加速批准用于r/rDLBCL治疗，EMA也批准其有条件使用。 5 Imvotamab是IgM的CD20xCD3-BsAb。体外诱导CDC能力强，细胞因子释放少，目前正在进行首次人体临床试验，安全性和耐受性良好。 6 Plamotamab是人源化IgG1的CD20xCD3-BsAb。I期临床试验正在评估其在血液恶性肿瘤患者中的安全性和耐受性，已在部分患者中显示出临床活性。 CD20-BsAbs的副作用及预防措施 副作用：抗CD20-mAbs毒性相对较低，常见副作用包括过敏反应、骨髓抑制和免疫抑制等，放射性标记抗体还有与辐射相关的毒性。 措施：可通过预先使用类固醇或抗组胺药物、缓慢输注等策略降低过敏反应发生率，对于低丙种球蛋白血症可考虑静脉注射免疫球蛋白替代治疗。 CD20嵌合抗原受体修饰的T细胞 图6 CD20 的 CAR 构建体 CD20 作为CAR-T细胞的靶标正在临床前和临床试验中探索。研究表明CD20 CAR-T细胞疗法是一种很有潜力的r/r-NHL治疗方法。CD20也是旨在降低抗原逃逸风险的CAR-T细胞免疫疗法的关键靶点。 表4 临床测试的靶向 CD20 的 CAR-T 疗法 CD20免疫疗法的耐药性 概述：耐药机制包括CD20抗原水平改变（如基因表达变化、替代剪接、内化和trogocytosis等）、免疫系统效应功能受损（如CDC和ADCC功能受影响）、遗传改变导致的信号通路变化以及肿瘤微环境的免疫抑制作用（如分泌抑制性细胞因子、过表达PD-L1等）。 图7 CD20 定向免疫疗法的耐药机制 应对耐药性的策略：积极探索新方法以提高免疫疗法的有效性，包括寻找新的治疗靶点、优化患者分层和采用联合治疗策略，如使用抑制补体调节蛋白的药物、联合免疫检查点抑制剂等。 与CD20免疫疗法的联合治疗策略 Science & Technology 常见联合治疗方案：①与R-CHOP、R-pola-CHP等方案用于治疗DLBCL和MCL；②与venetoclax、idelalisib等靶向药物联合用于治疗CLL；③在B-ALL治疗中也与化疗或酪氨酸激酶抑制剂联合使用；④与一些新型联合疗法联用，如R-DHAP与替西罗莫司联合治疗复发/难治性DLBCL。 药物相互作用与影响：联合使用的药物可能对CD20抗原表达产生双向影响，如泼尼松龙可上调CD20表达，而一些药物如伊布替尼、idelalisib等可下调CD20表达并抑制细胞毒性效应细胞，从而影响抗CD20mAbs的疗效。需要进一步研究药物诱导的细胞信号变化和CD20的表达调控关系。 结论与展望 CD20靶向免疫疗法在B细胞恶性肿瘤治疗中取得了显著进展，为复发/难治性患者提供了有效治疗选择，但也面临治疗相关并发症和副作用等挑战。 表5 CD20的传统mAb、双特异性抗体和CAR-T疗法的对比 深入理解不同类型治疗的活性决定因素和耐药机制，对于优化治疗选择和提高临床疗效至关重要。未来的关键方向包括联合小分子药物、同时靶向多个免疫治疗靶点，以提高治疗精度并降低复发风险，同时更好地理解反应和耐药的决定因素，以实现患者的精准选择和合理联合治疗。 关于仁域生物 成都仁域生物成立于2019年1月，是一家专注基因工程抗体技术和天然抗体库开发的公司，拥有优化的噬菌体展示抗体库技术和现代化的骆驼/羊驼养殖免疫基地。 公司核心技术平台包括全球最大的5000+天然驼源纳米抗体库(总库容＞3×10^12)、肿瘤细胞系免疫的骆驼免疫库、万亿级大容量全人源噬菌体展示scFv抗体库(总库容＞1×10^12)。 可为客户提供14天、100%成功率的先导抗体分子发现服务，彻底解决传统抗体定制的周期长、失败率高、成本高三大难题。目前已经成功完成300+靶点抗体筛选项目！ 科研专用—万亿级天然抗体库产品 （一步到位，轻松搭建基因工程抗体平台） 2024.10~11月产品限量供应 protocol 获取 / 产品咨询 邮箱｜find@renyubio.com 电话｜19136178673 地址｜成都市经开区科技产业孵化园 参考文献 Dabkowska A, Domka K, Firczuk M. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Front Immunol. 2024 Apr 4;15:1363102.  Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020 Jun;105(6):1494-1506. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021 Feb;21(2):161-181. Basu B, Angeletti A, Islam B, Ghiggeri GM. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are? Front Immunol. 2022 Feb 11;13:805697.  关注我们，持续更新相关内容

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse after conventional chemotherapy regimens. This paradigm shift is characterized by the emergence of innovative therapies like CAR T-cell therapy and bispecific antibodies, which have demonstrated remarkable efficacy in targeting and eradicating lymphoma cells. CAR T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered to recognize and attack cancer cells. This personalized treatment has shown significant promise, especially for individuals who have undergone extensive previous therapies. One notable example is Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy approved for use in patients with relapsed or refractory follicular lymphoma. Clinical trials have highlighted its ability to induce durable remissions, with some patients experiencing long-term remission even after multiple prior therapies. LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the follicular lymphoma pipeline domain. Key Takeaways from the Follicular Lymphoma Pipeline Report DelveInsight's follicular lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for follicular lymphoma treatment. Key follicular lymphoma companies such as Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others are evaluating new follicular lymphoma drugs to improve the treatment landscape. Promising follicular lymphoma pipeline therapies such as Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others are under different phases of follicular lymphoma clinical trials. In August 2024, the company expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with FL who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024 based on the positive Phase III results. In June 2024, a consortium of Eugene Private Equity and Korea Development Bank Private Equity announced that they would acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million). In February 2024, Incyte announced that it had entered into an asset purchase agreement with MorphoSys AG, which gives Incyte exclusive global rights for tafasitamab. Incyte will now recognize revenue and cost for all US commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments. In September 2023, OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate. The ONM-501 first-in-human trial is a multicenter Phase Ia/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid tumors and lymphomas. OncoNano is the sponsor of the clinical trial, and Regeneron will supply cemiplimab. In May 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. Under the terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the Chinese territory. Janssen will make an upfront payment of USD 245 million that will be accounted for in the second quarter as a research and development expense. Additional future payments will be based upon achieving certain development, regulatory, and sales milestones, as well as tiered royalty payments on worldwide net trade sales, excluding Greater China. Request a sample and discover the recent advances in follicular lymphoma treatment drugs @ Follicular Lymphoma Pipeline Report The follicular lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage follicular lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the follicular lymphoma clinical trial landscape. Follicular Lymphoma Overview Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This cancer is characterized by the growth of abnormal lymphoid follicles, which can disrupt normal lymphatic function. While the exact causes of follicular lymphoma are not fully understood, certain factors may increase the risk, including age (most commonly affecting adults over 60), a family history of lymphoma, and potential environmental factors such as exposure to pesticides or chemicals. Symptoms of follicular lymphoma can vary widely but may include painless swelling of lymph nodes in the neck, armpit, or groin, unexplained weight loss, night sweats, fatigue, and fever. Some patients may remain asymptomatic for extended periods, as this type of lymphoma can progress slowly. Diagnosis typically involves a combination of physical examinations, blood tests, imaging studies (like CT scans), and a biopsy of affected lymph nodes. The biopsy helps determine the subtype and stage of the lymphoma, which is crucial for planning treatment. Treatment for follicular lymphoma depends on the stage of the disease and the patient's overall health. Options may include watchful waiting for asymptomatic cases, chemotherapy, immunotherapy (such as monoclonal antibodies), and targeted therapies. In some cases, stem cell transplants may be considered for patients with more aggressive forms or those who do not respond to initial treatments. Given the indolent nature of follicular lymphoma, ongoing management, and regular monitoring are vital for achieving the best possible outcomes. Find out more about follicular lymphoma treatment drugs @ Drugs for Follicular Lymphoma Treatment A snapshot of the Follicular Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging follicular lymphoma pipeline therapies @ Follicular Lymphoma Clinical Trials Follicular Lymphoma Therapeutics Assessment The follicular lymphoma pipeline report proffers an integral view of the follicular lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Follicular Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitors, Phosphatidylinositol 3 kinase gamma inhibitors, Emt protein-tyrosine kinase inhibitors, Interleukin 15 receptor agonists, Histone deacetylase inhibitors, Rad51 recombinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Enhancer of zeste homolog 2 protein inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death 1 receptor antagonists, T lymphocyte stimulants, Alkylating agents, DNA cross-linking agents Key Follicular Lymphoma Companies: Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others. Key Follicular Lymphoma Pipeline Therapies: Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others. Dive deep into rich insights for new drugs for follicular lymphoma treatment, visit @ Follicular Lymphoma Drugs Table of Contents For further information on the follicular lymphoma pipeline therapeutics, reach out @ Follicular Lymphoma Treatment Drugs Related Reports Follicular Lymphoma Market Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies including Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED